Safety and efficacy of mesenchymal stem cells in the treatment of chronic pancreatitis and its associated pain

Ended Cooperative Agreement Awarded Last action

Award ID
UG3DK136705
Recipient
Awarding agency
Obligated
$327,555

Award facts

Completion date
Funding agency
Office of the Director National Institutes of Health, Department of Health and Human Services
Place of performance
Charleston, SC 29425, USA

Award details come from USAspending.gov.

Description

As the agency reported it.

Abstract
Chronic pancreatitis (CP) is a debilitating disease characterized by irreversible morphological changes (fibrosis) and persistent inflammation in the pancreas. Abdominal pain is one of the predominant symptoms and presents in up to 90% of CP patients and is associated with the heavy use of opioids. Chronic pain can cause opioid dependence, anxiety, depression and reduced quality of life. Although opioids are effective for acute pain, they are not effective as a long-term treatment strategy. There is a critical need for more effective, safer, and non- addictive therapeutic options for people who suffer from chronic pain associated with CP or other diseases. The use of mesenchymal stromal cells (mscs) in treating pain represents a promising novel intervention as increasing evidence demonstrates that MSC therapy can effectively target several injury pathways in a variety of fibroinflammatory diseases while reducing pain, something that most pharmacological interventions cannot accomplish. Mscs exert protective effects through the release of pro-mitotic, antiapoptotic, anti-inflammatory, and immunomodulatory soluble factors, to mitigate metabolomic and oxidative stress imbalance. Data from animal models and clinical trials support the outstanding and durable effects of MSC infusion in the suppression of chronic inflammation and neurological pain associated with various diseases. Our own animal study demonstrated that MSC infusion significantly reduces pain and improves fibrosis and pancreatic volume in mouse models of CP. However, whether the infusion of mscs can be used as a novel approach to relieving chronic pain and improve pancreatic function in CP patients has not been tested and will be the focus of this study. Based on compelling data, our hypothesis is that treatment with mscs reduces chronic pain and improves pancreatic fibrosis and function by their ability to target multiple injury pathways. The objective of this study is two folds: (i) prepare for the clinical trial (UG3 phase, year 1), and determine the safety and efficacy of MSC therapy in patients with painful CP (UH3 phase, year 2-5). Another critical part of the clinical trial phase will be to define the mechanisms by which mscs relieve multiple injuries in the pancreas by measuring changes of peripheral blood mononuclear cells (pbmcs), especially monocyte subsets and serum proinflammatory cytokine profiles of treated patients, with the goal of identifying biochemical pathways and serum biomarkers of response to MSC therapy. This study may help develop novel non-addictive cellular therapy for chronic pancreatitis and pain.

Transactions

Action Obligated Date
Amendment $0
Amendment $0
Amendment $0
Original award $327,555

Quick answers

Who received award UG3DK136705?

UG3DK136705 was awarded to The Medical University Of South Carolina by National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) on September 15, 2023.

How much is award UG3DK136705 worth?

$327,555 has been obligated on UG3DK136705.

Which agency awarded UG3DK136705?

National Institute of Diabetes and Digestive and Kidney Diseases (National Institutes of Health) awarded UG3DK136705, with funding from Office of the Director (National Institutes of Health).

On GovTribe

See this award's full record

  • Every transaction and subaward
  • The recipient's other awards and teaming partners
  • Similar grant awards
  • Ask GovTribe AI about this award
Try for free Login